Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patient-reported outcome measures (PROMs) are increasingly used to monitor patients with ATTRwt, assess individual trajectories, and determine disease progression. Such information allows closer monitoring of their risk of functional decline, frailty, recurrent falls, repeated hospitalizations, increased mortality, and high caregiver burden.”
This review highlights the limitations of traditional heart failure patient-reported outcomes in capturing the multisystem burden of ATTR-CM and evaluates emerging disease-specific questionnaires (Amylo-AFFECT-QOL, ATTR-QOL, and ITALY) for comprehensive patient assessment.
No abstract yet. The journal hasn't published one we can show.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Zeis et al. (2025) conducted a review in Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Patient-Reported Outcomes (PROs) and ATTR-targeted therapies (tafamidis, acoramidis, vutrisiran) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: